Loading...
Back to narrative

1SXP: Leadership Transition Will Support Future Profitability And Operational Discipline

Advanced Drug Delivery And Capacity Investments Will Shape Future Success

1SXP logo
1SXP
AnalystConsensusTarget
Not Invested
Published 16 Dec 2024

Update shared on 06 Dec 2025

Fair value Decreased 3.11%
Previous
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-37.7%
7D
-4.4%

Analysts have modestly reduced their price target for SCHOTT Pharma KGaA by approximately €0.90. This reflects slightly lower assumptions for revenue growth, profit margins, and future valuation multiples, alongside a marginally higher discount rate.

What's in the News

  • The Supervisory Board has appointed long-serving SCHOTT executive Christian Mias as CEO of SCHOTT Pharma Management AG, effective May 1, succeeding retiring CEO Andreas Reisse (Key Developments).
  • Outgoing CEO Andreas Reisse, with the SCHOTT Group since 1987 and head of the Pharmaceutical Systems division since 2010, will retire upon reaching the statutory age limit after overseeing the 2023 Frankfurt listing of SCHOTT Pharma AG & Co. KGaA (Key Developments).
  • The leadership transition plan includes a months-long handover period, with Reisse actively supporting Mias to help ensure continuity and stability for employees and operations (Key Developments).
  • New CEO Mias brings more than 20 years of management experience, including senior roles across SCHOTT business units in Brazil and the United States, where he focused on process optimization, productivity gains, and earnings quality (Key Developments).

Valuation Changes

  • Fair Value Estimate has fallen slightly from approximately €29.19 to €28.28 per share, reflecting more conservative assumptions.
  • Discount Rate has risen marginally from about 5.81 percent to 5.83 percent, modestly increasing the hurdle rate applied to future cash flows.
  • Revenue Growth has been trimmed slightly from roughly 9.17 percent to 9.12 percent per year, indicating a small downward adjustment in top line expectations.
  • Net Profit Margin has edged down from about 17.38 percent to 17.30 percent, implying a minor reduction in projected profitability.
  • Future P/E Multiple has decreased slightly from around 23.67x to 23.08x, indicating a modestly lower valuation multiple applied to earnings.

Have other thoughts on SCHOTT Pharma KGaA?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.